<i>STAT3</i> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Theresa A. Proia(AstraZeneca (South Korea)), Patricia McCoon(AstraZeneca (Brazil))
Cited by 52
Related Papers
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial
|Journal for ImmunoTherapy of Cancer|2018|286